TNGX NASDAQ
Credit Risk of going bust: lower than 53% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.04 (down 99.8%), Tango Therapeutics, Inc. would be worth roughly what it owes.
Total debt $32.0M against a stock market value of $3.86B.
Distance to default 5.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 93.4%; Altman Z'' 25.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02215
US
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Crystal Adam | M-Exempt | 27,000 | $5.20 | 2026-10-01 |
| Crystal Adam | S-Sale | 26,400 | $24.45 | 2026-10-01 |
| Crystal Adam | S-Sale | 600 | $25.32 | 2026-10-01 |
| Crystal Adam | M-Exempt | 27,000 | $5.20 | 2026-10-01 |
| Newcomb Jessica | S-Sale | 700 | $22.80 | 2026-09-22 |